Metagenomi not panicking despite Moderna ending deal

2 May 2024

mRNA specialist Moderna (Nasdaq: MRNA) has opted to end its collaboration with fellow US biotech Metagenomi on primary hyperoxaluria type 1 (PH1).

Rights to develop the PH1 program, as well as all other rights granted under the collaboration, will be returned as part of the termination.

"With this announcement, we continue to have the opportunity to accelerate our mission to become the premier gene editing company"The original deal - reportedly worth up to $70 million upfront and potentially $3 billion in total - was agreed in late 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK